|
 Previous Article | Table of Contents | Next Article 
Lysis of neuroblastoma cell lines by human natural killer cells activated
by interleukin-2 and interleukin-12
AR Rossi, F Pericle, S Rashleigh, J Janiec and JY Djeu
Department of Pediatrics, University of Florida, Gainsville.
Neuroblastoma is the most common extracranial, solid tumor in children.
Despite intensive chemotherapy and bone marrow transplantation, the 5- year
projected survival rate is 20% to 25%. In vitro studies have shown enhanced
natural killer cell (NK) lysis of tumor cells after exposure of NK cells to
interleukin-2 (IL-2). In vivo studies have demonstrated similar immunologic
effects but have also revealed severe toxicities associated with the use of
IL-2. IL-12 is a newly described cytokine that has several properties,
including the ability to act synergistically with IL-2 in generating
lymphokine-activated killer cells (LAK) against known tumor targets. We
investigated the role of IL- 12 in the generation of peripheral blood
mononuclear cell (PBMC) lysis of neuroblastoma cell lines. PBMC were
activated with IL-12 alone and in combination with IL-2. Whereas IL-12
alone produced only modest enhancement of NK cell cytotoxicity, the
combination of IL-2 and IL-12 was most effective in activating NK cell
lysis of neuroblastoma cell lines. Further, we showed that large granular
lymphocytes were the effector cells involved in target cell lysis. Finally,
the CD18 molecule was shown to be critical in the lysis of neuroblastoma
cells by activated PBMC.
Volume 83,
Issue 5,
pp. 1323-1328,
03/01/1994
Copyright © 1994 by The American Society of Hematology
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
C. A. Lengacher, M. P. Bennett, L. Gonzalez, D. Gilvary, C. E. Cox, A. Cantor, P. B. Jacobsen, C. Yang, and J. Djeu
Immune Responses to Guided Imagery During Breast Cancer Treatment
Biol Res Nurs,
January 1, 2008;
9(3):
205 - 214.
[Abstract]
[PDF]
|
|
|
|
|
|
|
D. Valteau-Couanet, C. Leboulaire, K. Maincent, M. Tournier, O. Hartmann, J. Benard, F. Beaujean, C. Boccaccio, L. Zitvogel, and E. Angevin
Dendritic cells for NK/LAK activation: rationale for multicellular immunotherapy in neuroblastoma patients
Blood,
September 18, 2002;
100(7):
2554 - 2561.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. M. Wigginton, J.-W. Park, M. E. Gruys, H. A. Young, C. L. Jorcyk, T. C. Back, M. J. Brunda, R. M. Strieter, J. Ward, J. E. Green, et al.
Complete Regression of Established Spontaneous Mammary Carcinoma and the Therapeutic Prevention of Genetically Programmed Neoplastic Transition by IL-12/Pulse IL-2: Induction of Local T Cell Infiltration, Fas/Fas Ligand Gene Expression, and Mammary Epithelial Apoptosis
J. Immunol.,
January 15, 2001;
166(2):
1156 - 1168.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. S. Wang, D. A. Frank, and J. Ritz
Interleukin-2 enhances the response of natural killer cells to interleukin-12 through up-regulation of the interleukin-12 receptor and STAT4
Blood,
May 15, 2000;
95(10):
3183 - 3190.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. J. Robertson, C. Cameron, M. B. Atkins, M. S. Gordon, M. T. Lotze, M. L. Sherman, and J. Ritz
Immunological Effects of Interleukin 12 Administered by Bolus Intravenous Injection to Patients with Cancer
Clin. Cancer Res.,
January 1, 1999;
5(1):
9 - 16.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. J. Robertson and J. Ritz
Interleukin 12: Basic Biology and Potential Applications in Cancer Treatment
Oncologist,
February 1, 1996;
1(1):
88 - 97.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
